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Background: Standard of care for management of ADH identified on percutaneous biopsy is 
surgical excision. Research efforts have focused on utilizing strict multidisciplinary review to 
identify patients at lowest risk for upgrade that may benefit from omission of surgery. However, 
having an ipsilateral breast cancer, in addition to the site of ADH, has been an exclusion criterion 
for consideration of observation over excision of the site of ADH. 
Methods: This retrospective analysis examined patients who had both a breast cancer and an 
additional site of ADH in the same breast diagnosed on percutaneous biopsy, who underwent 
surgical excision of both areas at our institution from 2008-2018. Imaging characteristics (size of 
cancer, size of ADH, distance between cancer and ADH, percutaneous biopsy technique) and 
pathologic features (histologic subtype of cancer, cancer grade and prognostic markers, extent of 
ADH, presence of necrosis or micropapillary features in the ADH) were reviewed from the 
biopsy, as well as the final surgical pathology at the site of ADH excision to determine features 
associated with ADH upgrade. 
Results: Sixty-two women had biopsy proven ADH and a breast cancer at separate sites in the 
same breast over the 10-year study period. The overall upgrade rate at the site of ADH was 
17.7% (n=11), with 9 cases to ductal carcinoma in situ (DCIS) and 2 to invasive breast cancer 
(IBC). The most common associations with upgrade were the presence of ipsilateral DCIS over 
IBC (p=0.034), using ultrasound guidance for biopsy of ADH (p=0.019), and the presence of cell 
necrosis in the ADH (p=0.039). Neither the radiographic size of the ADH nor the distance of the 
ADH from the ipsilateral cancer were associated with upgrade. The group at lowest risk for 
upgrade had stereotactic biopsy of the site of ADH and no necrosis associated with ADH, which 
resulted in 0% upgrade rate. 
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Conclusion: When an ipsilateral breast cancer is present, the upgrade rate at the site of ADH is 
on par with reported contemporary ADH upgrade rates without ipsilateral breast cancer present. 
Similar to those studies of ADH alone, upgrade was significantly associated with biopsy 
modality and presence of ADH necrosis. When considering the ipsilateral breast cancer, upgrade 
rate for ADH was not affected by the size of the cancer, size of atypia, or distance between the 
ipsilateral malignancy and atypia. This suggests that omission of surgical excision for ADH in 
patients with concurrent breast cancer may be appropriate, like those with isolated ADH, when a 
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Chapter I: Introduction 
Breast cancer is the second most common cancer among women in the United States, 
with more than 252,710 cases of invasive breast cancer (IBC) and 63,410 cases of ductal 
carcinoma in situ (DCIS) diagnosed in 2017.1 This translates into nearly 1 in 8 women in the 
United States being diagnosed with a breast cancer over the course of her lifetime.1 Standard of 
care for the surgical management of breast cancer is either mastectomy or lumpectomy followed 
by whole breast radiation, also known as breast conserving therapy (BCT).2,3 
As imaging techniques and technology have improved, additional imaging abnormalities 
are being identified more frequently during the work up for an ipsilateral breast cancer. Standard 
of care for the management of an abnormal breast imaging finding, with an ipsilateral breast 
cancer, is percutaneous image-guided core needle biopsy, or surgical excision.4 More than 1 
million percutaneous breast biopsies are performed for women with an abnormal imaging 
finding, 10-15% of which yield a finding of atypical hyperplasia.5 
When women have undergone surgical excision for atypical ductal hyperplasia (ADH) 
identified on percutaneous biopsy, the upgrade rate to underlying malignancy has ranged wildly 
in the literature from 7-87%.6-8 Therefore, the National Comprehensive Cancer Network 
(NCCN) guidelines recommends surgical excision for patients with ADH diagnosed on 
percutaneous biopsy due to this risk of upgrade to DCIS or IBC.9 However, as imaging and 
biopsy techniques continue to improve, the need for routine excision of all ADH has been called 
into question. 
Multiple studies, including two studies performed at this institution, using more 
contemporary imaging and biopsy techniques, with strong multidisciplinary review, have 
identified lower upgrade rates, and attempted to identify patients at lowest risk for upgrade to 
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DCIS or IBC who may avoid surgical excision.6,8,10-18 Attention has been focused on a 
combination of specific pathologic and radiographic features of ADH. Based on our data, 
patients with pathologic findings of ADH on percutaneous biopsy who have undergone extensive 
multidisciplinary review and meet criteria for low upgrade risk are offered observation and 
chemoprevention over surgical excision.16,18 
One exclusion criteria in prior trials for consideration of observation of ADH over 
excision has been the presence of an ipsilateral DCIS or IBC. Historically, excision of both the 
ipsilateral breast cancer and the site of ADH has been performed, either with one large 
lumpectomy, two separate lumpectomies, or mastectomy. This accomplishes the goal of 
removing the known cancer and ruling out additional malignancy at the site of the ADH. The 
concern has always been that the woman may be at increased risk of underlying malignancy at 
the site of atypia if there is an ipsilateral malignancy. However, for many women desiring breast 
conservation, excising the area of ADH in addition to the ipsilateral cancer may result in 
significantly more breast tissue being removed, leading to a more profound cosmetic defect and 
breast asymmetry, or the inability to perform BCT at all, necessitating mastectomy. 
The purpose of this study is to identify our institution’s upgrade rate of ADH to DCIS or 
IBC when there is concurrent ipsilateral but separate site of DCIS or IBC. This upgrade rate has 
not been defined in the literature. If this rate of upgrade is significantly elevated there is 
justification for additional excision. However, if this rate of upgrade is low, or if a low risk for 
upgrade subset can be identified, then omission of surgical excision of the site of ADH may 
potentially be offered. This would allow women to have a more cosmetically appealing surgical 




Chapter II: Literature Review 
Definitions of Breast Cancer 
Breast cancer is the most common cancer diagnosis among women in the United States, 
with more than 252,710 cases of invasive breast cancer (IBC) and 63,410 cases of ductal 
carcinoma in situ (DCIS) diagnosed in 2017, and the second most common cause of cancer 
death.1 This translates into nearly 1 in 8 women in the United States being diagnosed with a 
breast cancer over the course of her lifetime. The normal structure of the breast is composed of 
lobules and ducts. To form a breast cancer, the tumor progresses from a benign proliferative state 
to in situ then invasive cancer through a series of genetic alterations and protein expression 
patterns.19 
DCIS is carcinogenic cells that are contained within the duct and have not spread through 
the basement membrane into the surrounding fatty tissue of the breast. Because DCIS is still 
contained within the normal structure of the breast, more than 90% of these lesions are identified 
on screening imaging. More rare presentations of DCIS include palpable masses, nipple 
discharge, or nipple skin changes.20 IBC is a heterogenous group of epithelial breast 
malignancies, defined as the ability of the carcinogenic cells to invade adjacent normal tissue 
(such as the duct or the lobule), and can metastasize to sites distant to the breast. In general, IBC 
can be subclassified into invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), 
based on the loss of e-cadherin expression. IDC is the more common histologic subtype, 
accounting for approximately 80% of all IBC.21 DCIS is associated with an IBC in 
approximately 80% of cases of IDC, either within or around the invasive cancer.22  
4 
 
To further describe either the DCIS or IBC, the Nottingham grading system is applied to 
reflect the degree of differentiation of the carcinoma. Grading incorporates assessment of tubule 
formation, degree of nuclear atypia, and mitotic activity and is assigned on a scale of I-III.23 
Prognostic markers are also obtained, which can help to define the clinical behavior of the tumor 
and guide systemic therapy recommendations. Commonly obtained markers include estrogen 
receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 gene or 
ERBB2 (HER2), and Ki-67. 70-80% of IBC are positive for ER and/or PR and 15-30% are 
HER2 amplified. HER2 is only routinely obtained for IBC, not DCIS. Ki-67 is a proliferation 
index, which, like histologic grade, can represent the growth rate or aggressive nature of the 
cancer. 
Treatment of Breast Cancer 
 Management of breast cancer requires a multidisciplinary approach that incorporates 
local and systemic therapy for optimal outcomes. For the surgical management of breast cancer, 
before the 1970’s, all patients were treated with a radical mastectomy, which included removal 
of the breast, regional lymph nodes, underlying muscle, and overlying skin. NSABP B-04 
relaxed this procedure into the now termed “modified radical mastectomy” where the skin and 
muscle are spared. Following this, several randomized clinical trials, which started accrual in the 
1970’s established that the extent of local therapy did not affect patient survival, the most 
important of which was NSABP B-06.2 B-06 was a comparison of lumpectomy with or without 
breast irradiation to total mastectomy. Patients with early stage breast cancer were randomized to 
one of these three arms from 1976-1984. At 20 years follow up, there continues to be no 
significant difference in overall survival, disease-free survival, or distant disease-free survival 
between the three groups. However, for the lumpectomy groups, those who received whole 
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breast radiation had improved local control. This landmark trial supports standard of care for the 
management of breast cancer to be either complete removal of the breast (mastectomy) or 
removal of the tumor and preservation of the remaining breast tissue (lumpectomy) followed by 
whole breast radiation, also defined as breast conserving therapy (BCT). 
Definitions of Atypical Ductal Hyperplasia 
 ADH is an epithelial proliferative lesion that forms in the terminal duct lobular unit that 
is found on 8-17% of core needle biopsies.24 Similar to DCIS, ADH demonstrates both cytologic 
atypia and architectural changes; but the atypia are quantitatively and qualitatively insufficient 
for a diagnosis of DCIS. Therefore, to differentiate DCIS from ADH, the size criteria of atypia 
involving only 1 or 2 ducts and measures less than 2mm may be used to diagnose ADH.24,25 
Because of this, sampling error with core needle biopsy demonstrating ADH can occur, resulting 
in an upgrade to DCIS or IBC on surgical excision when the full lesion is evaluated. In addition, 
the interobserver concordance for ADH is notoriously poor.26 The risk of upgrade has ranged 
widely in the literature from 7-87%. Advancements have been made in biopsy techniques and 
more sophisticated imaging modalities such as magnetic resonance imaging (MRI) and 
tomosynthesis are being used to target breast abnormalities. Refining diagnostic criteria of ADH 
and subspecialization of pathologists have improved interobserver concordance rate. In addition, 
more contemporary studies have focused on multidisciplinary concordance between the 
radiographic and pathologic findings. These more contemporary studies have identified an 
upgrade rate, or finding DCIS or IBC at the time of surgical excision, to be 18-39%.8,11,12,27-30 
ADH is also a non-obligate precursor to breast cancer and represents a global increased risk of 
future breast cancer in either breast. 
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Treatment of Atypical Ductal Hyperplasia 
 When ADH is diagnosed on percutaneous core needle biopsy, surgical excision has been 
considered standard of care to rule out underlying malignancy.9 However, given that most ADH 
cases diagnosed by percutaneous biopsy are not upgraded to DCIS or IBC, routine surgical 
excision is concerning for overtreatment for the majority of women. Multiple studies have 
attempted to define a favorable subgroup with ADH on core needle biopsy who would not 
benefit from surgical excision, or be at lowest risk for upgrade. Some studies identified patient 
demographic information such as age at diagnosis or personal or family history of breast cancer 
as risk for upgrade.11,12,15,31,32 Other studies used radiographic features such as size of the target 
lesion, the percent of the target that was removed by the biopsy, or number of cores 
removed.13,15,29,33 Even other studies used pathologic features such as the number of foci of 
ADH, or the presence of individual cell necrosis or micropapillary features.6,8,10,13,17 
With these findings, multivariate models have been proposed, the two most common 
from MD Anderson Cancer Center (MDACC) and Mayo Clinic. In 2011, Nguyen and colleagues 
identified 140 patients with ADH and found the lowest risk of upgrade occurred in patients with 
>95% removal of the target lesion, the target lesion not being associated with a mass, no 
cytologic atypia, and no individual cell necrosis. They found that patients meeting these criteria, 
regardless of the extent of involvement, had minimal risk of upgrade to DCIS or IBC of <3% 
compared to the overall upgrade rate of 13.2%.13 Pena and colleagues at Mayo then published 
their findings in a series of 399 patients, with an overall upgrade rate of 16%. They found the 
lowest upgrade rate of <5% in patients with no individual cell necrosis and either 1 focus of 




The long-term safety of omission of surgical excision for ADH has also been described 
by MDACC, in the low-risk subgroup defined by Nguyen. In a study by Menen and colleagues, 
the risk of subsequent cancer was not elevated in the group that underwent observation compared 
to the group that required surgical excision. This suggests that omission of surgical excision in a 
select group of patients with the diagnosis of ADH, meeting strict radiologic and histologic 
criteria, may be an oncologically safe option.35 
This has led to investigation of our own institutional upgrade rate in attempt to identify 
features that define our lowest risk group. Retrospective review of 124 percutaneous biopsies 
with ADH from 2006-2015 identified an overall upgrade rate of 17.7%.16 The patients at lowest 
risk for upgrade were those with the target lesion < 1 cm in size, > 50% of the target lesion 
removed by the biopsy, < 3 foci of ADH, and no individual cell necrosis. Though this was a 
small number in our studies, none of these patients upgraded to DCIS or IBC at the time of 
surgical excision.18 Based on our findings, women who meet these criteria after undergoing 
rigorous multidisciplinary review are offered observation and counseling with chemoprevention 
in our high-risk breast cancer prevention clinic over surgical excision. 
 However, if a woman has an ipsilateral breast cancer and breast imaging identifies an 
additional abnormality in that same breast, and BCT is desired, percutaneous biopsy is 
recommended to diagnose that additional abnormality. If ADH is identified on core needle 
biopsy, surgical excision is routinely recommended of that area, in addition to the area of cancer. 
Women with an ipsilateral breast cancer and a separate site of ADH have been excluded from 




Over the 10-year study period, 62 women were identified with both an ipsilateral breast 
cancer and a diagnosis of ADH on percutaneous biopsy at a site remote to the known 
malignancy, 37 (59.7%) in the left breast and 26 (41.9%) in the right breast. The majority of 
women were Caucasian (74.2%) with a mean age of 59.2 years (std 11.08, range 30-86). Twenty-
seven (43.5%) had a family history of breast cancer in a first or second degree relative and 3 





Chapter III: Methods 
A single institution retrospective review was performed from January 2008-August 2018.  
All women, age 18-90, diagnosed with ADH on percutaneous biopsy, with a separate site of 
ipsilateral DCIS or IBC, who underwent surgical excision of both sites were identified. Patients 
were excluded if they were male, had other types of atypia including atypical lobular hyperplasia 
or lobular carcinoma in situ, did not have the site of ADH excised, or if the ADH was associated 
with the malignancy and not at a separate site in the same breast. All breast imaging was 
reviewed for biopsy modality, size of the target lesion (both cancer and ADH), and distance of 
ADH from ipsilateral malignancy. All pathology reports from the percutaneous biopsy and from 
the time of definitive surgery were reviewed to assess the histologic tumor subtype, grade, 
prognostic markers, and presence of DCIS associated with the invasive component, as well as the 
presence of DCIS or IBC at the biopsy site of ADH on final pathology to define upgrade rate to 
underlying malignancy at the time of surgery. In addition, ADH-specific features on biopsy 
pathology were captured including number of atypical foci, presence of individual cell necrosis, 
and micropapillary features. Additional clinical features were noted including age at diagnosis, 
personal and family history of breast cancer, and ethnicity. 
 Statistical Methods 
Categorical variables were summarized using frequencies. Chi-square and Fisher’s exact 
test was performed when appropriate to test for associations between categorical demographic, 
clinical, radiologic, pathologic characteristics of patients, and upgrade rate at the site of ADH. 
Student’s t test was performed as univariate analysis for continuous variables. Multivariable 
logistic regression analysis was performed to identify variables that were significantly associated 
10 
 
with upgrade to underlying malignancy. All analyses were performed with SAS software version 
9.4 (SAS Institute Inc. Cary, NC) and a p-value of 0.05 was used to determine statistical 




Chapter IV: Results 
Invasive ductal carcinoma was the most common histologic subtype of ipsilateral 
malignancy (n=40, 64.5%) followed by DCIS (n=18, 29%) and invasive lobular carcinoma (n=5, 
8.1%). Most cancers were strongly hormone receptor (ER/PR) positive (n=54, 87.1%) and very 
few IBC were HER2 amplified (n=3, 7%). The surgical procedure for management of the sites of 
cancer and ADH was most commonly mastectomy (n=35, 56.5%), followed by two separate 
lumpectomies (n=16, 25.8%), and one large lumpectomy (n=11, 17.7%, Table 1). 
The average size of the IBC or DCIS was 2.03 cm (std 1.79, median 1.50, range 0.3-9.0 
cm) and the average distance between the site of malignancy and the site of ADH was 4.55 cm 
(std 2.44, median 4.0 range 1.0-12.0 cm, Table 2). The biopsy modality for diagnosis of ADH 
was evenly distributed between stereotactic (n=21, 33.9%), sonographic (n=21, 33.9%), and 
magnetic resonance (n=20, 32.3%) guidance (Table 2). Most had only 1-2 foci of ADH (n=44, 
71%), and a minority had micropapillary features (n=4, 6.7%) or individual cell necrosis (n=5, 
8.3%, Table 3).  
Eleven women were found to have an underlying malignancy at the site of ADH on final 
surgical pathology, for an overall upgrade rate of 17.7% (95% CI 8.2-27.3%): 9 to DCIS and 2 to 
IBC. The remaining 51 women either had residual atypia or benign findings (Figure 1). There 
were no demographic details that were significantly associated with upgrade, but there was a 
non-significant trend toward younger patients and those of non-Caucasian ethnicity having a 
higher risk of upgrade (Table 4). The ipsilateral malignancy, histologic tumor type and tumor 
size were not statistically significantly associated with upgrade, however, when comparing 
invasive (IDC and ILC) to non-invasive (DCIS) cancer, DCIS was significantly associated with 
upgrade (p=0.034, Table 4). The presence of DCIS associated with IBC, tumor grade, and 
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prognostic markers were all not significant. When focusing on the ADH characteristics, neither 
the size of the ADH on imaging nor the distance between the ADH and the cancer were 
significant for upgrade. The biopsy modality for diagnosis of ADH was significantly associated 
with upgrade, with ultrasound guidance being much more likely to upgrade to malignancy 
(p=0.019, Table 2). ADH associated with necrosis was significantly associated with higher 
upgrade rate to underlying malignancy (p=0.039), but the presence of micropapillary features or 
the number of foci (extent) of ADH was not (Table 3). 
Table 1. Patient characteristics 
 All patients with 
ADH and ipsilateral 
malignancy 
Upgrade group No upgrade 
group 
P value 
No. of patients (%) 62 (100) 11 (17.7) 51 (82.3)  













































































Table 2. Tumor characteristics 
 All patients with 





















































































*1 patient with missing imaging to determine clinical tumor size in the no upgrade group 




Table 3. ADH characteristics 









Distance between ADH and cancer, 








ADH target size, cm [mean (std)]*** 1.77 (2.06) 0.99 (0.41) 1.91 (2.21) 0.962 
























































***2 patients with imaging and slides not available to review ADH size, foci, micropapillary 


























Table 4. Bivariate analysis of variables associated with upgrade 
Factors Unadjusted OR 95% CLs p-value 
Age <50 at diagnosis 1.037 0.1908,5.6364 0.9664 
Non-Caucasian ethnicity 3.030 0.7766,11.8249 0.1105 
Clinical tumor size >1cm 0.7982 0.1796,3.5487 0.7672 
DCIS tumor type 4.3636 1.1182,17.0278 0.0339 
HR positive cancer 0.4000 0.0634,2.5239 0.3296 
Distance between ADH 
and cancer <3cm 
2.400 0.6049,9.5224 0.2131 
ADH biopsy with US 
guidance 
12.3077 1.3733,110.30 0.0249 
ADH size >1cm 1.3474 0.3218,5.6420 0.6832 
ADH extent (>2 foci) 1.7619 0.4387,7.0763 0.4246 
ADH with necrosis 8.8128 1.2665,61.3166 0.0279 
 
Table 5. Multivariate analysis of variables associated with upgrade 
Factors Adjusted OR 95% CLs p-value 
ADH biopsy with US 
guidance 44.8986 2.1709,928.58 0.0138 
DCIS tumor type 11.5209 1.1509,115.32 0.0161 








Chapter V: Discussion  
The overall upgrade to underlying malignancy at the site of ADH was 17.7% when there 
was an ipsilateral breast cancer present. As hypothesized, this upgrade rate was not significantly 
more elevated in this cohort with an ipsilateral malignancy, when compared to the contemporary 
upgrade rate of 18-39% in the prior studies without the presence of an ipsilateral malignancy. 
This also matches our institutional upgrade rate of 17.7% when our own upgrade rate was 
examined.16 Historically, it has been assumed that the site of ADH was at higher risk for upgrade 
because of the presence of an ipsilateral cancer, which warranted surgical excision of the site of 
ADH. To the best of my knowledge, this is the first study to have defined this upgrade rate, 
particularly with attention to the multidisciplinary features assessed. 
We found that though not statistically significant, younger patients were at higher risk of 
upgrade. This is in contrast to Ko and colleagues who found age >50 to be significantly 
associated with upgrade.32 Older age was also found to be associated with upgrade in subsequent 
studies by Chae, Mcghan, Menes, and Uzan.11,12,15,31 Ethnicity was not reported as significant in 
other studies, and though it did not reach significance in this cohort, being of non-Caucasian 
ethnicity was associated with a 3-fold risk of upgrade. 
When considering the pathologic features associated with the ADH, many studies noted 
the size of the targeted lesion and the extent of the ADH (ie. >2 foci) to be associated with 
upgrade.8,10,17,33 While the extent of ADH trended toward significance in this cohort with an 
unadjusted OR of 1.7, the radiographic size of ADH on preoperative imaging was essentially 
inversely related to upgrade. We did find the presence of individual cell necrosis in the ADH 
carried an 8-fold risk of upgrade, which was consistently identified by others to be associated 
with upgrade as well.6,8,10,13,17 Also, having a breast specific pathologist confirming the diagnosis 
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of ADH for each patient included in the cohort significantly decreases the concern about 
interobserver variability and undercalling a DCIS or IBC as ADH. 
When considering the additional radiographic features of ADH, I was not able to quantify 
how much of the target associated with ADH was excised by the biopsy for this study, which has 
been found to be significant in multiple studies.13,16,29,33,34 As expected, when the target is under-
sampled, these lesions were more likely to upgrade. A surrogate for undersampling could be 
biopsy modality used to sample the target. In our practice, stereotactic and MR-guided biopsies 
routinely use vacuum-assistance, larger-bore needles, and remove >6 cores. Biopsy with 
sonographic-guidance does not routinely utilize vacuum-assistance and frequently < 6 cores are 
removed with 12-14-gauge needle, resulting in less of the target being evaluated before surgical 
excision. The indication for the biopsy at the site of ADH were not recorded. Frequently in 
practice, calcifications would be sampled using stereotactic biopsy, mass or non-mass 
enhancement with no ultrasound correlate would be sampled using MR-guidance, and masses 
would be sampled using sonographic guidance. To a breast radiologist, a mass seen on 
ultrasound would have the most concern for underlying malignancy of these three presentations. 
Therefore, it is not surprising that patients who had ADH diagnosed by ultrasound biopsy were at 
12-fold risk of upgrade. 
Unique to our study is the presence of an ipsilateral malignancy. Focusing on the features 
of the malignancy, ADH was more likely to upgrade when DCIS was present, either alone, or in 
association with an IBC. Although I know of no studies that suggests DCIS is more likely to be 
multifocal or multicentric compared to IBC, DCIS can present with skip lesions, whereas IBC is 
more likely to be a discrete entity. To meet inclusion criteria for this study, the ADH and site of 
malignancy were required to be separate distinct lesions > 1cm apart, which should be far 
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enough apart to not include DCIS skip lesions which are really all one entity. Interestingly, all 
other malignancy features were non-significant, including tumor size, grade, hormone receptor or 
HER2 status. In addition, even when the ADH was in closer proximity to the ipsilateral cancer, 
there does not appear to be a higher risk of upgrade, than if the ADH was identified without an 
ipsilateral breast cancer. 
Therefore, based on these findings, it is reasonable to consider omission of surgical 
excision in a select group of patients with percutaneous biopsy diagnosis of ADH with a 
concurrent ipsilateral breast cancer, similar to the stratification models being developed for 
solitary ADH.  We need to continue to develop the criteria for both presentation types to identify 
the patients at a low risk for upgrade. This data significantly contributes to the assessment, 
approach, and appropriate identification of patients that can safely undergo active surveillance 
and avoid surgical excision. Unlike those with a solitary site of ADH, patients with an ipsilateral 
breast cancer and ADH who undergo lumpectomy for management of their cancer will 
frequently have additional adjuvant therapy, including whole breast radiation and endocrine 
therapy for at least 5 years. Each of these adjuvant therapies will provide additional protection to 
the breast to decrease the risk of recurrence or future breast cancers. 
When focusing on the group that is typically offered observation over excision at our 
institution (ADH target <1cm, no ADH necrosis, <3 foci of ADH), this would result in an 
upgrade rate of 8% in this cohort (2/25 patients). If we excluded those who underwent US guided 
biopsy, as this biopsy modality was significantly associated with upgrade, the resulting upgrade 
rate is 0%. Though this was a limited number of patients in this study (16/62 patients, 26%), it 
appears that this would be a safe group to elect for observation of the site of ADH, with a very 
low risk of missing an underlying malignancy in the ipsilateral breast. Caution should also be 
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taken when the ipsilateral malignancy is DCIS, as this was also significantly associated with 
upgrade. When excluding patients with ipsilateral DCIS from this group, the upgrade rate 
continues to be 0%. 
We have learned from Menen’s study that not excising a site of ADH can be 
oncologically appropriate. In their study, 125 women underwent active surveillance after 
percutaneous biopsy diagnosed ADH. Compared to a group that underwent surgical excision, the 
likelihood of developing a cancer either at the site of biopsy or in the ipsilateral breast were not 
different (p=0.49 and 1.00) between the groups. Only 24% of women in this study received 
chemoprevention.35 Therefore, it seems likely that for women meeting strict multidisciplinary 
criteria, who have a low risk of upgrade could avoid excision of the site of ADH, particularly 
when they will receive additional adjuvant therapy as treatment for the ipsilateral malignancy. 
Limitations 
This is a retrospective review from a single institution with a relatively small sample size. 
Also, breast imaging reports do not consistently note the percent of the target excised, or the 
percent of the target remaining after percutaneous biopsy, so this parameter was not able to be 
included in the analysis. However, size of the target and biopsy modality can be correlates for 
how well the target would be sampled. With ultrasound-guided biopsy, this is the least likely to 
have vacuum-assistance, which results in less tissue to removed and more potential for under-
sampling, and therefore more likely to upgrade. 
Considerations for Future Research 
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For future research, further investigation can be made into the radiographic 
characteristics such as percent of the target sampled in this patient cohort. In addition, the 
application of MR enhancement at the site of the ADH may also be a useful tool to decide about 
need for excision. Application of these findings to clinical practice can then begin. All patients 
will be prospectively identified and delegated into groups appropriate for observation or 
recommend excision. All patients are then screened appropriately after their cancer treatment for 
recurrence or new malignancy. As we start to accumulate patients in the group who do not have 
the site of ADH excised, we will be able to compare outcomes of ipsilateral breast cancer 
recurrence or future malignancy to those who underwent excision of the site of ADH to 
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